ALK buys shares in new biotech firm with experienced leader

A one-year-old biotech firm can now count one of Denmark's largest pharmaceutical companies among its owners. ALK hopes the company is sitting on an affective allergy treatment.

Søren Mouritsen, CEO of Betamab, is happy to get ALK onboard as an investor in the company. Photo: Betamab/ PR

Allergy group ALK is continuing its hunt for assets to strengthen its future product portfolio.

At the start of the year, ALK collaborated with US-based X-Chem to develop the allergy drugs of tomorrow.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles